NU Skin Enterprises vs Usana Health Sciences
NU Skin Enterprises is the larger business, with $1.49bn of revenue in fiscal 2025 against $925m for Usana Health Sciences (1.6 times as much). Usana Health Sciences grew faster (8.3% against -14.3%). NU Skin Enterprises kept more of each dollar of sales as profit: a net margin of 10.8% against 1.2%. Usana Health Sciences carries less debt relative to equity (2.6% against 27.9%).
| Latest fiscal year | NU Skin EnterprisesNUS, 2025 | Usana Health SciencesUSNA, 2025 |
|---|---|---|
| Revenue | $1.49bn | $925m |
| Revenue growth | -14.3% | 8.3% |
| Net income | $160m | $10.8m |
| Operating margin | 4.4% | 4.0% |
| Net margin | 10.8% | 1.2% |
| Return on equity | 22.0% | 2.0% |
| Free cash flow | $46.0m | $8.5m |
| Cash | $239m | $158m |
| Total debt | $225m | $14.0m |
| Debt to equity | 27.9% | 2.6% |
| Dividend per share | — | — |
| Dividend yield | 5.0% | — |
| Share buybacks | $20.0m | $27.5m |
| Employees | 2,800 | 1,570 |
| Market value | $233m | $276m |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | 55 (Moderate) | 72 (Strong) |
| Insider trades, 12 months | 1 buys, 3 sales | 0 buys, 16 sales |